ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts. Hu B, Wiesehofer M, de Miguel FJ, Liu Z, et al. Cancer Res 2024 Feb 15. doi: 10.1158/0008-5472.CAN-23-0438.

Read + Share

Amedeo Smart

Independent Medical Education

Hu B, Wiesehofer M, de Miguel FJ, Liu Z, et al. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts. Cancer Res 2024 Feb 15. doi: 10.1158/0008-5472.CAN-23-0438.
PMID: 38359163